Xbrane Biopharma (Q2 initial take): Higher revenue and EBIT than pencilled - Redeye

Xbrane's Q2 results came in ahead of our estimates on revenue and EBIT, but the report reinforces the case's central risk: without an October FDA approval for Lucamzi, the SEK60m Fenja loan maturing in January 2027 has no clear repayment source.

Länk till analysen i sin helhet: https://www.redeye.se/research/1174849/xbrane-biopharma-q2-initial-take-higher-revenue-and-ebit-than-pencilled?utm_source=finwire&utm_medium=RSS